Correlation of Anti-Cyclic Citrullinated Antibody with Hand Joint Erosion Score in Rheumatoid Arthritis Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: To examine the correlation between radiological joint damage and serological parameters in early rheumatoid arthritis (RA). Methods: This retrospective study reviewed the records of 216 patients diagnosed with RA and classified them according to disease duration: group 1, ≤ 24 months; group 2, > 24 months; and group 3, all patients combined. The extent of joint damage was assessed from plain radiographs using a modified version of the Larsen method and compared among groups. Results: The mean radiographic joint damage score was significantly higher in patients who had established RA (10.1 points) compared with those who had early RA. In group 1, the inflammatory parameters, erythrocyte sedimentation rate, and C-reactive protein were positively correlated with the joint damage score, but rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody were not. A subgroup analysis revealed that the anti-CCP positive patients in groups 1 and 2 had greater joint damage scores than did the anti-CCP negative patients, but no difference in RF was observed between subgroups. Anti-CCP positivity was not significantly correlated with joint damage sores in group 3. Conclusions: Anti-CCP positivity was significantly correlated with more severe joint damage at diagnosis. A correlation was observed between the radiological joint damage score and inflammatory parameters in early and established RA, indicating that anti-CCP can serve as a diagnostic tool and predict structural joint damage. These findings suggest anti-CCP positive patients should receive aggressive therapeutic intervention. (Korean J Intern Med 2010;25:201-206)
Abstract
Background/Aims: To examine the correlation between radiological joint damage and serological parameters in early rheumatoid arthritis (RA). Methods: This retrospective study reviewed the records of 216 patients diagnosed with RA and classified them according to disease duration: group 1, ≤ 24 months; group 2, > 24 months; and group 3, all patients combined. The extent of joint damage was assessed from plain radiographs using a modified version of the Larsen method and compared among groups. Results: The mean radiographic joint damage score was significantly higher in patients who had established RA (10.1 points) compared with those who had early RA. In group 1, the inflammatory parameters, erythrocyte sedimentation rate, and C-reactive protein were positively correlated with the joint damage score, but rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody were not. A subgroup analysis revealed that the anti-CCP positive patients in groups 1 and 2 had greater joint damage scores than did the anti-CCP negative patients, but no difference in RF was observed between subgroups. Anti-CCP positivity was not significantly correlated with joint damage sores in group 3. Conclusions: Anti-CCP positivity was significantly correlated with more severe joint damage at diagnosis. A correlation was observed between the radiological joint damage score and inflammatory parameters in early and established RA, indicating that anti-CCP can serve as a diagnostic tool and predict structural joint damage. These findings suggest anti-CCP positive patients should receive aggressive therapeutic intervention. (Korean J Intern Med 2010;25:201-206)
참고문헌 (30)
- Kvien TK, "Epidemiology and burden of illness of rheumatoid arthritis", Pharmacoeconomics, 22, pp.1~12 (2004)
- Arnett FC, "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis", Arthritis Rheum, 31, pp.315~324 (1988)
- De Rycke L, "Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations", Ann Rheum Dis, 63, pp.1587~1593 (2004)
- Forslind K, "BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP)", Ann Rheum Dis, 63, pp.1090~1095 (2004)
- Shmerling RH, "Testing for anti-cyclic citrullinated peptide antibodies: is it time to set this genie free?", Arch Intern Med, 169, pp.9~14 (2009)
- Ates A, "Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis", Clin Rheumatol, 26, pp.499~504 (2007)
- Avouac J, "Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review", Ann Rheum Dis, 65, pp.845~851 (2006)
- Suzuki A, "Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis", Nat Genet, 34, pp.395~402 (2003)
- Lindqvist E, "Prognostic laboratory markers of joint damage in rheumatoid arthritis", Ann Rheum Dis, 64, pp.196~201 (2005)
- Meyer O, "Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis", Arthritis Res Ther, 8, pp.R40~ (2006)
- Bongi SM, "Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA", Autoimmunity, 37, pp.495~501 (2004)
- Quinn MA, "Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome", Rheumatology (Oxford), 45, pp.478~480 (2006)
- Rau R, "A modified version of Larsen’s scoring method to assess radiologic changes in rheumatoid arthritis", J Rheumatol, 22, pp.1976~1982 (1995)
- Padyukov L, "A geneenvironment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis", Arthritis Rheum, 50, pp.3085~3092 (2004)
- Emery P, "The Roche Rheumatology Prize Lecture. The optimal management of early rheumatoid disease: the key to preventing disability", Br J Rheumatol, 33, pp.765~768 (1994)
- van der Heide A, "The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial", Ann Intern Med, 124, pp.699~707 (1996)
- Lee DM, "Clinical utility of the anti-CCP assay in patients with rheumatic diseases", Ann Rheum Dis, 62, pp.870~874 (2003)
- Hoffman IE, "Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis", Clin Chem, 51, pp.261~263 (2005)
- Nell VP, "Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis", Rheumatology (Oxford), 43, pp.906~914 (2004)
- O’Dell JR, "Therapeutic strategies for rheumatoid arthritis", N Engl J Med, 350, pp.2591~2602 (2004)
- van Aken J, "Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis", Ann Rheum Dis, 63, pp.274~279 (2004)
- Nell VP, "Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis", Ann Rheum Dis, 64, pp.1731~1736 (2005)
- Nienhuis RL, "A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor", Ann Rheum Dis, 23, pp.302~305 (1964)
- Young BJ, "Antikeratin antibodies in rheumatoid arthritis", Br Med J, 2, pp.97~99 (1979)
- Vincent C, "Anti-perinuclear factor compared with the so called “antikeratin” antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides", Ann Rheum Dis, 58, pp.42~48 (1999)
- Schellekens GA, "Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritisspecific autoantibodies", J Clin Invest, 101, pp.273~281 (1998)
- Caspi D, "Synovial fluid levels of anticyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis", Arthritis Rheum, 55, pp.53~56 (2006)
- Liao KP, "Anticyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis", Ann Rheum Dis, 67, pp.1557~1561 (2008)
- Syversen SW, "Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers", J Rheumatol, 36, pp.1769~1784 (2009)
- Zhao J, "Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis", Clin Rheumatol, 29, pp.33~38 (2010)